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Abstract: The introduction of immunotherapeutic agents has provided renewed hope for 
Chronic lymphocytic leukemia ﬂ  udarabine-refractory patients. Several clinical trials have 
shown that alemtuzumab is a more effective option compared to combination chemotherapy for 
treatment of patients who have relapsed or who are refractory to ﬂ  udarabine, including those 
with poor prognostic factors. Although there are signiﬁ  cant potential toxicities associated with 
alemtuzumab, such as infusional reactions and the risk of cytomegalovirus (CMV) reactiva-
tion, most are manageable. Pre-treatment anti-pyretics and anti-histamines are recommended to 
prevent or mitigate the acute infusional reactions associated with intravenous infusion. Recent 
use of alemtuzumab via the subcutaneous route has been shown to be well tolerated and has 
yielded similar response rates to the infusional method of administration. Prophylaxis with 
thrimethoprim/sulphamethoxazole (TMP/SMZ) as well as valacyclovir or a similar anti-viral 
can prevent many of the opportunistic infections seen in early trials. Reactivation of CMV infec-
tion can be effec  tively managed with monitoring and early treatment. Chemo-immunotherapy 
combination with alemtuzumab has been tested and demonstrated unprecedented clinical results 
in relapsed and refractory patients. The use of this agent earlier in the algorithm of patients 
with these characteristics should be considered. Future areas of research will include the use of 
alemtuzumab in combination with other monoclonal antibodies and other targeted therapies.
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Background
Chronic lymphocytic leukemia (CLL) is a malignancy that results in accumulation of 
mature, monoclonal B-cells in blood, lymphnodes, spleen and bone marrow produc-
ing lymphocytosis, adenopathy, organomegaly and progressive bone marrow failure 
(Kipps 2001). The basic physiopathologic defect in CLL is resistance of neoplastic 
cells to programmed-cell death or apoptosis. Median survival of these patients is about 
10 years but it largely varies from one patient to another: from less than 3 years to a 
normal life expectancy. Therefore, treatment should be individualized on the basis of 
the risk to each patient (Montserrat 2002; Byrd et al 2004).
Historically, the clinical course for the majority of patients with CLL has been 
predictable, with a response to initial treatment, eventual recurrence, reduced likeli-
hood of response with subsequent treatments, and shorter duration of response with 
each remission. Retreatment typically yields progressively less satisfactory response 
than the prior treatment, eventually leading to refractory disease.
For many years alkylating agents-based regimens utilizing chlorambucil (CHL) or 
cyclophosphamide (CTX) were the mainstays of treatment for CLL which resulted in a 
complete response (CR) rate in less than 10% along with palliation of symptoms, and 
only a modest, if any, impact on survival (Knaspe et al 1974; Oken and Kaplan 1979).Biologics: Targets & Therapy 2008:2(1) 42
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Clinical research has been aimed at developing new 
treatments that prolong survival and potentially cure patients 
with CLL. Response to treatment has been assessed in clini-
cal trials by the National Cancer Institute-Working Group 
(NCI-WG) criteria published more than 10 years ago (Cheson 
et al 1996).
A response-driven approach has been commonly used, 
based on the observation that patients who achieve CR live 
longer that those who achieve partial remission (PR) or those 
who fail treatment.
The introduction of purine analogs provided a new treat-
ment option for CLL. Purine analogs have shown increased 
numbers of CRs compared with alkylating agents, particularly 
when administered to previously untreated patients. Until the 
purine analogs were developed, no treatment was available that 
was effective in CLL patients who were resistant to alkylating 
agents. Fludarabine (FAMP) has been the most commonly 
used in this class of drugs, and it was rapidly shown to be 
capable of achieving a good response rate in patients who were 
refractory to CHL. In the context of second line therapy, FAMP 
has been shown to compare favorably to other available treat-
ments in terms of effectiveness, side effects and cost (Grever 
et al 1985; Keating et al 1989; Saven and Piro 1993).
Three phase III studies have shown that FAMP is supe-
rior to CHL and to a combination of CTX, adriamycin, 
and prednisone (CAP) regarding the number of complete 
remissions and the duration of remission in ﬁ  rst-and second-
line treatment of CLL (Johnson et al 1996; Rai et al 2000; 
Leporrier et al 2001). However, none of these studies could 
demonstrate a beneﬁ  t on median overall survival (OS).
The majority of patients who achieve remission following 
FAMP treatment are known to suffer a relapse after a median 
of 20–30 months (Rai et al 2000).
It is important to separate refractory from relapsing 
disease. Whereas treatment of patients with relapsing dis-
ease, particularly when the progression-free-interval has 
been long (eg,  12 months), can be envisaged as in newly 
diagnosed patients, patients with truly refractory disease 
have an extremely poor prognosis and require immediate 
intervention. As mentioned before, resistance to CHL or other 
alkylating agents at low/standard doses can sometimes be 
overcome by purine analogs. For example, in the study of Rai 
et al comparing FAMP to CHL, 46% of patients failing CHL 
did respond to FAMP, whereas only 7% of the 29 patients 
who were crossed from FAMP to CHL had a response (Rai 
et al 2000). For patients who become refractory or who 
demonstrate a primary resistance to FAMP, the prognosis is 
generally poor (Keating et al 2002a).
Now resistance to FAMP is emerging as a problem in an 
increasing number of patients. Other approaches combine 
FAMP with other chemotherapy agents and explore these 
novel combinations to capitalize on possible synergistic 
effects. The most effective salvage regimens are considered 
to be the combinations of purine analogs and CTX. (Keating 
et al 2002a)
Three recently published phase III trials comparing 
FAMP and CTX with FAMP alone showed superiority of 
the combination in untreated patients with B-CLL (Eichhorst 
et al 2006; Catowsky et al 2007; Flinn et al 2007).
One small report suggested that cladribine (2-CDA) was 
effective in FAMP refractory patients but this data was dis-
puted by larger series (Juliusson et al 1992; Delannoy et al 
1993; O’Brien et al 1994).
Alternative therapies are needed for such patients, pref-
erably using agents whose mechanism of action does not 
overlap with those of prior chemotherapies. In fact, patients 
resistant to alkylating agents have a lower response rate to 
FAMP than sensitive patients, suggesting a ﬁ  nal common 
pathway of resistance (Keating et al 1993).
Alemtuzumab in relapsed/
refractory CLL
One such approach by monoclonal antibodies is now offered. 
Alemtuzumab is a humanized monoclonal antibody against 
CD52, an antigen expressed at high density on most normal 
and malignant B and T lymphocytes, but not on hematopoi-
etic stem cells (Gilleece et al 1993). Binding of alemtuzumab 
to CD52 on target cells may cause cell death by 3 different 
mechanisms: complement activation (Heit et al 1986), 
antibody-dependent cellular cytotoxicity (Greenwood et al 
1993), and apoptosis (Rowan et al 1998).
The difference in clinical results between rituximab, a 
chimeric human-mouse anti-CD20, and alemtuzumab may 
be related to the relative expression of CD20 and CD52 on 
malignant lymphocytes; the level of CD20 expression in 
patients with B-CLL is low, in comparison with other B-cell 
lymphomas and normal B-cells (Rossmann et al 2001). 
Alemtuzumab has been approved for the treatment of CLL 
that is refractory to FAMP.
Intravenous alemtuzumb
Alemtuzumab, also called Campath 1-H, was initially 
investigated in 3 multi-center phase I trials in non-Hodgkin 
lymphoma (NHL) at doses ranging up to 240 mg per 
week. Following these early NHL trials, two multicenter 
phase II trials (protocol 125-K32-005 and 125-K32-009) Biologics: Targets & Therapy 2008:2(1) 43
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were conducted in Europe and USA, respectively. These 
trials treated a total of 149 patients with a variety of lym-
phoproliferative disorders.
Osterborg and colleagues published a report on a subset 
of 29 patients treated on study 125-K32-005, who had CLL 
and who had relapsed after an initial response to chemo-
therapy (n = 8) or who were refractory (n = 21) (Osterborg 
et al 1997). Due to the fact that FAMP had been available 
in Europe only since 1994, only 3 of these 29 patients had 
been previously treated with FAMP. All patients were treated 
with alemtuzumab at a dose of 30 mg intravenously over 2 
hours 3 times per week (TIW) for a maximum of 12 weeks. 
Among the 8 relapsed patients, 3 (38%) showed a response 
while 9 of 21 (43%) with refractory disease were able to 
achieve a response using alemtuzumab. It was also shown 
that CLL cells were rapidly eliminated from blood in 97% 
of the patients and a bone marrow CR was obtained in 37% 
while splenomegaly resolved in 32% of patients. On the 
contrary, lymphoadenopathy resolved in only 7% of patients. 
The median response duration was 12 months (range 6–25+). 
Although World Health Organization (WHO) grade 4 neu-
tropenia and thrombocytopenia developed in 3 (10%) and 2 
(7%) patients respectively, these toxicities resolved in most 
responding patients during continued alemtuzumab treatment. 
In all patients a profound lymphopenia ( 0.5 × 103/μL) was 
observed. Bacterial septicemia was detected in 4 patients 
while 2 patients developed opportunistic infections.
Twenty-four patients with B-cell CLL (n = 23) or T-cell 
prolymphocytic leukemia (n = 1) were enrolled in the US 
phase II trial (125-K32-009) (Rai et al 2002). These patients 
were treated at 6 US centers with a target dose of 30 mg TIW 
for up to 16 weeks. Differently from the European trial, all of 
these patients were previously treated with FAMP and 71% 
had either not responded to FAMP or had responded initially 
but relapsed within 6 months of treatment. The remaining 
29% of patients had been sensitive to a previous treatment 
with FAMP but when they relapsed they had not responded 
to subsequent chemotherapy regimens. Partial responses 
were observed in 8 of 24 patients (33%). The median time 
to achieve response was 3.9 months (range 1.6–5.3 months) 
and the median duration of response was 15.4 months (range 
4.6–38.0 months). Median time to disease progression was 
19.6 (range 7.7–42 months) and median survival time was 
35.8 months (range 8.8 to  47.1 months). Antibiotic pro-
phylaxis was not mandated in this study and opportunistic 
infections were observed in 41.7% of patients. Pulmonary 
infections were the most common: there were 3 proven 
cases of Pneumocystis carinii and 1 suspected; 1 case of 
fungal infection was also recorded. Opportunistic infections 
were more common in patients who didn’t have clinical 
beneﬁ  cial response to monoclonal antibody. Keating and 
co-workers reported the results of an international study of 
alemtuzumab in 93 patients with CLL who were refractory 
to FAMP (Keating et al 2002b). Those patients were treated 
with intravenous alemtuzumab at a target dose of 30 mg TIW 
for up to 12 weeks. Also required for entry into this study 
was prior treatment with an alkylating agent. These were a 
group of heavily pre-treated patients with the median num-
ber of prior regimens being three (range 2–7) while 46% of 
patients had received multiple FAMP treatments. Almost half 
of the patients (48%) had never responded to any nucleoside 
analog-based regimen. All patients were required to stay on 
infection prophylaxis involving TMP/SMZ and famciclovir 
from day 8 of treatment to at least 2 months after completion 
of alemtuzumab therapy. The overall response rate (ORR) 
was 33% (31/93), with CR achieved in 2% (2/93). Median 
time to disease progression was 4.7 months for the intent-
to-treat population and 9.5 months for responders. Median 
survival for responders was 32 months, which exceeds the 
8- to 9-month median survival time reported for patients who 
failed FAMP. Lymphocytosis completely resolved in 83% of 
patients. Peripheral blood was cleared of malignant lympho-
cytes in 26 of 28 responders (93%) and in 34 of 40 patients 
(85%) with stable disease. Among the 31 responders, 48% 
completely cleared CLL cells from the bone marrow, and an 
additional 23% showed a reduction in malignant lymphocytes 
of at least 50% in bone marrow. Other major sites of disease 
also showed marked improvement with alemtuzumab therapy. 
Splenomegaly and hepatomegaly were completely resolved 
or reduced by at least 50% in 82% and 75% of patients, 
respectively. There was an inverse correlation between 
lymph node size and the likelihood of response. While 91% 
of patients whose largest lymph node measured less than 20 
mm experienced improvement of at least 50%, only 10% of 
patients with lymphnodes greater than 50 mm achieved more 
than 50% reduction in lymph node size. Among patients with 
cytopenias at baseline, 55% achieved more than 50% increase 
from baseline values, which illustrates improvement in bone 
marrow function with alemtuzumab treatment. Moreover, the 
majority of patients experienced resolution of B symptoms 
and fatigue, including those who did not achieve NCI-WG 
criteria response (67%). Infusion-related adverse events were 
very common but typically of mild or moderate in severity 
and generally diminished with time. Infections developed 
in 51 patients (55%); approximately half were mild to mod-
erate and half were more severe. Grade 3 or 4 infections Biologics: Targets & Therapy 2008:2(1) 44
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developed in signiﬁ  cantly more patients who did not respond 
to alemtuzumab (22 of 62 non-responders) than in responders 
(3 infections in 31 responders; p   0.01). Unlike the early 
studies with alemtuzumab in CLL cited above, prophylaxis 
against viral infection and Pneumocistis carinii (PCP) was 
required in this large pivotal trial and made a considerable 
difference in the incidence of PCP infections. Only 1 case 
of PCP was reported and this occurred in a patient who did 
not receive prophylaxis as outlined in the study. Overall 11 
patients developed opportunistic infections during the treat-
ment period and another 7 patients developed opportunistic 
infections in the post-treatment follow-up period. The most 
commonly reported event in this context was reactivation 
of CMV occurring in 7 patients, all appearing during the 
treatment period. Five of the cases resolved and 2 resulted in 
discontinuation of alemtuzumab with subsequent withdrawal 
from the study.
The results of treatment with alemtuzumab were also 
reported in a series of 78 patients with a variety of advanced 
or refractory chronic lymphoproliferative disorders. Alem-
tuzumab was given at 30 mg TIW intravenously for a 
minimum of 4 weeks and a maximum of 12 weeks, depend-
ing on response. Pre-medication with acetaminophen and 
diphenhydramine was required prior to each infusion and 
all patients were given prophylactic antibiotic coverage with 
TMP/SMZ and valacyclovir (Ferrajoli et al 2003).
CLL was the most common (n = 42) diagnosis in this 
series of 78 heavily pre-treated patients who had received a 
median of three (range 1–9) prior therapies. Among these 42 
patients with CLL, 19 were considered sensitive to, while 23 
were considered refractory to, FAMP. Among the subgroup 
of patients with CLL, there was a 31% (13/42) ORR with 
CR occurring in 2 patients (5%), PR in 10 patients (24%) 
and nodular PR in 1 patient (2%). Of the 19 patients with 
CLL that were “FAMP sensitive”, 2 CR and 5 PRs were 
achieved for an ORR of 37%. In those 23 patients who were 
considered “FAMP resistant”, there were no CRs and 6 PRs 
for an ORR of 26%.
As in previous studies clearance of blood lymphocytosis 
was achieved in a large proportion (84%) of the total patient 
population while nearly half the patients (49%) achieved 
resolution of the bone-marrow disease. A decrease in the size 
of enlarged spleen and liver by 50% or more occurred in 56% 
and 59% of patients, respectively, while lymphadenopathy 
decreased by at least 50% in 39% of patients. Seventy-one 
per cent of CLL patients developed proven or clinically 
suspected infection. CMV reactivation was the most com-
mon viral infection, occurring in 29% of 42 CLL patients. 
All of these patients responded to intravenous ganciclovir 
or foscarnet. Other infectious toxicities reported for the 
entire group of 78 patients were 17 episodes of bacteremia 
in 11 patients, 11 episodes of pneumonia in 10 patients, 
3 cases of herpes virus infections, and 1 case of invasive 
aspergillosis.
In this study also, infusion-related adverse events were 
common. Fever occurred in 85% and rigors in 42% of 
patients. Other immediate events included rash (42%), nausea 
(35%), dyspnea (31%), hypotension (18%), and headache 
(7%). Cardiovascular toxicity was seen in 3 patients (chest 
pain but no ischemic heart disease, congestive heart failure, 
depressed systolic ejection fraction at echocardiographic 
evaluation), all of whom had T-cell malignancies. Hemato-
logical toxicity included grade 3 (19%) and grade 4 (15%) 
neutropenia while grade 3 and 4 thrombocytopenia occurred 
in 28% and 13%, respectively. Persistent lymphopenia 
resulted in all patients.
Several additional phase II studies have been performed 
in FAMP-refractory patients. In one trial by McCune et al 
(2002), 23 heavily pretreated patients with relapsed or refrac-
tory CLL or prolymphocytic leukemia were treated with 
alemtuzumab 30 mg 3 times weekly for up to 12 weeks. All 
of the 18 B-CLL patients had failed FAMP therapy within 
6 months prior to initiation of this study. Nine of 17 evalu-
able patients (53%) had an objective response, including 6 
CR (35%).
In a recently published study by Moreton et al (2005), 
91 patients with relapsed or refractory CLL (of which 48% 
were refractory to purine analog therapy) were treated with 
alemtuzumab with the goal of eradicating detectable disease 
using minimal residual disease (MRD) ﬂ  ow cytometry. 
After a median 9 weeks of treatment, 32 patients (35%) 
achieved CR and 17 patients (19%) reached PR according 
to NCI-WG criteria. MRD ﬂ  ow cytometry demonstrated 
blood and bone marrow MRD negativity in 18 responding 
patients (20%; among 12 CR and 6 PR). Median survival 
for patients who had achieved MRD-negative CR was 
not reached, compared with 60 months for patients with 
MRD-positive CR, 70 months for patients with PR, and 
15 months for non-responders (NRs) (p = 0.0007). Treat-
ment-free survival was signiﬁ  cantly longer for patients 
achieving a MRD-negative CR (not reached), compared 
with those with MRD-positive CR (20 months), PR (13 
months), and non-responders (6 months) (p   0.0001). 
The OS of patients achieving MRD-negative CR was 84% 
at 60 months. The absence of lymphadenopathy correlated 
well with achieving MRD negativity: 13 of 33 patients Biologics: Targets & Therapy 2008:2(1) 45
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(39%) who were free from lymphadenopathy achieved 
MRD-negative CR while none of the patients with bulky 
lymphadenopathy (less than 50 mm) achieved MRD-nega-
tive status. This study shows that treatment with alemtu-
zumab can lead to undetectable levels of MRD, which 
translates to longer OS and treatment-free survival among 
patients with relapsed/refractory CLL. Rigors and fever 
were the most common adverse events occurring in 76% 
of patients and were more frequently grade 1 or 2 in sever-
ity. Less frequent adverse events included fatigue (11%), 
dys  pnea (4%), headache (4%), dizziness (3%), broncho-
spasm (2%), and diarrhea (2%). Adverse events declined 
in frequency by the end of week 3 of therapy. Neutropenia 
below 1.0 × 109/L occurred in 43 (48%) patients and below 
0.5 × 109/L in 27 (30%). Granulocyte colony   stimulating 
factor (G-CSF) was administered to 18 (20%) patients 
with a median neutrophil count of 0.35 × 109/L (range, 
0.02–0.6) and the neutrophil count rose to a median of 
1.15 × 109/L (range, 0.5–9.2). Thrombocytopenia occurred 
in 65 (73%) and was less than 50 × 109/L in 41 (46%). 
Thirty-nine patients (43%) experienced 1 or more infec-
tious episodes during or within 1 month of completing 
alemtuzumab therapy. There were 19 mild (grade 1 or 2) 
infectious episodes and 33 severe (grade 3 or 4) episodes. 
A total of 8 (8%) patients developed CMV reactivation 
at a median of 34 days after the start of therapy (range 
14–58). One patient died from CMV pneumonitis and 
after this, screening with pre-emptive therapy for CMV 
reactivation was instituted. All cases of CMV reactivation 
detected on screening resolved on anti-viral therapy. There 
were 31 documented infections in the period following 
alemtuzumab among 21 (23%) patients (excluding infec-
tions occurring during neutropenia following subsequent 
stem cell transplantation). Infections following the cessa-
tion of alemtuzumab in non-MRD-negative CR patients 
occurred after a median of 9 months (range 1–41) and in 
the MRD-negative patients after a median of 3 months 
(range 1–12).
Subcutaneous alemtuzumab
Because of the virtual certainty of infusion-related reactions 
which occur at a very high fre  quency, even when patients 
are pre-treated with antihistamines and acetaminophen, 
inves  tigators have embarked upon studies to determine if 
alemtuzumab can be made more user-friendly when it is 
administered via the subcutaneous route.
The German CLL Study Group initiated the CLL2H 
trial to evaluate the subcutaneous (SC) application of 
alemtuzumab 30 mg TIW for a maximum of 12 weeks 
in ﬂ  udarabine-refractory CLL patients (Stilgenbauer et al 
2004). An intravenous dose-escalation schedule of 3, 10, 
and 30 mg was used and patients were then switched to the 
subcutaneous route of administration. This trial essentially 
duplicated the ‘pivotal’ trial conducted by Keating et al 
(2002b) but replaced the intra  venous route with the sub-
cutaneous route of administration. In an interim analysis 
of the ﬁ  rst 50 patients enrolled, there were 4% CR, 33% 
PR, 44% stable disease, and 18% progressive dis  ease. The 
median OS at the time of the report was 17.4 months and 
median pro  gression-free survival was 10.8 months. These 
results compare favorably with the Keating trial. Response 
rates similar to the overall study population were observed 
in patients with prognostic genetic subtypes (ie, deletions 
of 17p, 11q, and unmutated VH genes).
The UKCLL02 study assessed the safety and efﬁ  cacy of 
SC alemtuzumab in FAMP-refractory CLL (Sayala et al 2006). 
Subcutaneous alemtuzumab was given at a dose of 30 mg TIW 
for up to 24 weeks depending on 6-weekly marrow assess-
ments. Patients failing to respond to alemtuzumab could receive 
oral FAMP (40 mg/m2/day for 3 days every 4 weeks) combined 
with SC alemtuzumab. Of 53 patients (median age 64, range 
41 to 79) enrolled, 50 patients have completed therapy and 49 
were evaluable. Responses to alemtuzumab monotherapy (n = 
49) were 7 CR (5 MRD–, 2 MRD+), 15 PR (1 MRD–), 25 NR, 
and 2 patients died on treatment. Alemtuzumab was given for 
a median of 18.8 weeks (range 1.6–24) with a median dose of 
1370.5 mg (range 106–2323 mg). Seventeen patients (6 PRs 
and 11 NRs) received concurrent FAMP and alemtuzumab SC 
(2 courses FAMP median [range 1–3]). Two NR achieved a PR 
and 1 PR achieved a CR (MRD positive). Therefore the overall 
response rate for the whole cohort was 24/49 (49%) including 
6 MRD negative patients (5 CRs and 1 PR). 22/38 patients 
(58%) with poor risk deletions (11q- and/or 17p-) and/or p53 
dysfunction responded to treatment, including 5 patients who 
achieved MRD-negative CRs, 3 MRD-positive CR, and 14 PR. 
Serious infections during alemtuzumab monotherapy were: 
CMV reactivation (18), febrile neutropenia (10), invasive 
fungal infection (4), pneumonia (7), and septicemia (2); on 
the combination, CMV reactivation (3 cases) and septicemia 
in (1). All CMV reactivations resolved on antiviral therapy. 
Grade 3+ thrombocytopenia and neutropenia was seen in 26 
and 41 patients on alemtuzumab monotherapy as well as in 1 
and 5 patients on combined therapy, respectively. Hale et al 
(2004) studied the blood concentrations of alemtuzumab 
as well as anti-globulin responses following intravenous 
or subcutaneous routes of administration in CLL patients. Biologics: Targets & Therapy 2008:2(1) 46
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Subcutaneous alemtuzumab yielded serum concentrations 
similar to those achieved with intravenous alemtuzumab, 
although this was achieved with slightly higher cumulative 
doses. The dominant factor inﬂ  uencing bio-distribution and 
pharmacokinetics appears to be the extent of tumor burden. 
Subcutaneous alemtuzumab is more convenient and better 
tolerated and only rarely may be associated with formation 
of anti-alemtuzumab antibodies, particularly in those patients 
who were previously untreated. The 2 of 31 patients who 
demonstrated anti-alemtuzumab antibody (3.7 × 106 U/mL 
in 1 case and 4800 U/mL in the second one) on subcutaneous 
treatment, unlike the other patients, did not show signiﬁ  cant 
reductions in lymphocyte counts but had marked local skin 
reactions which did not diminish with continued therapy. 
All 30 patients tested for anti-antiglobulins after intravenous 
treatment with alemtuzumab were below the limit of detec-
tion (488 U/mL).
A reduced dose of 10 mg subcutaneous alemtuzumab has 
been tested in a small series of patients with refractory CLL 
(Cortelezzi et al 2005). Sixteen patients were enrolled. They 
had received a median of 3 prior lines of chemotherapy, all 
were refractory to alkylating agents, 14 were refractory to 
FAMP, while 2 were not allowed purine analogs containing 
regimen due to previous Coombs’ positive anemia. Half of 
the patients were also refractory to rituximab-containing 
regimens. All received at least 4 weeks of alemtuzumab, 12 
patients completed all 18 weeks of treatment.
The OR rate, according to NCI-WG criteria was 50%, 
including 25% CR. An objective response was documented 
in 50% of patients refractory to both alkylators agents and 
FAMP. Treatment was well tolerated.
These studies demonstrate that subcutaneous alemtu-
zumab, a more convenient alterna  tive to intravenous, is 
safe and appears to have similar efﬁ  cacy and an improved 
side-effect proﬁ  le compared with intravenous alemtuzumab. 
In addition, according to the Swedish study (Lundin et al 
2002), the subcutaneous route of administration may reduce 
healthcare costs.
Results reported with alemtuzumab administered as 
monotherapy are summarized in Table 1.
Chemo-immunotherapy 
with alemtuzumab
Combination with other drugs and/or monoclonal antibodies 
has being actively investigated to improve FAMP efﬁ  cacy. 
One of the ﬁ  rst indications of the activity of alemtuzumab 
in combination with FAMP came from a small study of 
6 patients with CLL refractory to either alemtuzumab or 
FAMP as single agents (Kennedy et al 2002). Five of the 
6 patients responded, including 1 CR, and complete mor-
phologic marrow responses were seen in another 3 patients 
with eradication of ﬂ  ow-cytometry-measurable disease in 2 
of them. Furthermore, 5 patients were alive at the 12-month 
follow-up. Toxicity during combined was acceptable with 
only 1 patient requiring hospital admission with Pseudomo-
nas bronchopneumonia during neutropenia.
Elter et al pursued the FAMP plus alemtuzumab combi-
nation further. FAMP was given at 30 mg/m2 intravenously 
daily on days 1–3, which was immediately followed by alem-
tuzumab at 30 mg given over 2 hours for 3 doses on days 1–3 
as well (FluCam regimen). Courses were repeated every 4 
weeks for a total of 6 rounds. In addition to evaluating clinical 
responses, MRD was measured using 4-color ﬂ  ow cytometry 
(Elter et al 2005). A total of 36 patients were treated in this 
phase II study, median age was 61 years, mean number of pre-
vious treatment was 2.6. Twenty-two patients had previously 
been treated with FAMP and 9 of them (41%) were refrac-
tory to FAMP treatment. Seventy-eight per cent of patients 
presented a Binet Stage C. All patients had extensive bone 
marrow inﬁ  ltration at baseline and the majority had lymphoad-
enopathy and/or splenomegaly. The ORR was 83% according 
to NCI-WG criteria with 11 patients achieving a CR (30%) and 
19 patients achieving PR (53%). Eight of the 12 patients who 
were refractory to prior therapy responded (4 CRs and 4 PRs). 
The majority of 22 patients pretreated with FAMP-contain-
ing regimen showed a good response to FluCam (6 CRs, 12 
PRs). Of the 9 patients who had been refractory to FAMP, 6 
responded to treatment. The lymphocytosis present at baseline 
resolved rapidly in most patients during the ﬁ  rst 2 cycles of 
therapy. The median OS for all patients was 35.6 months, time 
to progression (TTP) of 12.97 months. For patients achieving 
a CR the median OS was not reached and the median TTP was 
calculated as 21.9 months. Acute infusion-associated adverse 
effects (fever, chills, and skin reactions) were mild (grade 
1 or 2 CTC) in the majority of patients and were observed 
predominantly in association with initial alemtuzumab dose. 
The major toxicity in 140 assessable cycles was myelotoxicity 
with 44% grade 3–4 leukopenia, 26% grade 3–4 neutropenia 
and 305 grade 3–4 thrombocytopenia. There were only 2 CTC 
grade 3 subclinical CMV reactivations. Two patients showed 
fungal pneumonia due to Aspergillus fumigatus. One patient 
died from an Escherichia coli septic shock.
A phase II study to determine the efﬁ  cacy and safety of 
a 4-week combination regimen consisting of FAMP, CTX, 
and Campath-1H (FCC) in relapsed patients with CLL has 
been reported (Montillo et al 2007). Patients received FCC Biologics: Targets & Therapy 2008:2(1) 47
Alemtuzumab in FAMP refractory CLL
after a short period of alemtuzumab dose escalation, from 
3 mg to 10 mg to 20 mg on consecutive days. The FCC 
regimen consisted of FAMP 40 mg/m2/day PO (PO is OK) 
(Days 1–3), CTX 250 mg/m2/day PO (Days 1–3), followed by 
alemtuzumab 20 mg SC (Days 1–3). This combination was 
repeated on day 29 for up to 6 cycles. MRD was measured by 
4-color ﬂ  ow cytometry and consensus primer PCR. Twenty-
three patients were enrolled. The median age of the patients 
was 57.0 years (range, 42–79), 13/23 (56%) were male, 21/23 
(91%) had Binet stage B and C disease, and the median num-
ber of prior treatment regimens was 2 (range, 1–4). Among the 
18 evaluable patients, ORR was 79%, with 7 (37%) patients 
achieving CR, 7 (37%) PR, while 1 (5%) patient a PRn. Three 
patients had stable disease, while 1 showed progressive dis-
ease. MRD negativity was achieved in the bone marrow of 
4/14 (27%) patients. Grade III–IV neutropenia episodes were 
observed in 43% of the administered courses while grade III-
IV thrombocytopenia episodes were detected only in 8.0% of 
cycles. Four major infections were recorded: 2 sustained by 
Mycobacterium tuberculosis (1 cutis, 1 lung), 1 by Nocardia 
(lung), and 1 by E. coli (sepsis). CMV reactivation occurred 
in 6 patients: no CMV disease was recorded.
Monoclonal antibodies 
in combination
A main rationale for using monoclonal antibodies in combi-
nation is to overcome some of the limitations of single-agent 
monoclonal antibodies use (Nabhan and Rosen 2002). These 
include: a) variable expression of CD20 and CD52 on CLL 
cells of individual patients; b) synergistic activity in anatomic 
compartments such as lymphnode sites (where rituximab 
is expected to be more effective), versus marrow, (better 
clearance of malignant lymphocytes with alemtuzumab); 
c) engagement of distinct intracellular signaling pathways 
resulting in apoptotic cell death.
Faderl et al (2003) conducted an exploratory study of 
alemtuzumab plus rituximab in patients with relapsed and 
refractory chronic lymphoid malignancies. The schedule 
was empirically derived from established single-agent 
monoclonal antibody experience. Rituximab was given at 
375 mg/m2 weekly for 4 weeks with alemtuzumab at 30 mg 
intravenously twice weekly during weeks 2–4, preceded by 
a dose escalation of 3, 10, and 30 mg on 3 consecutive days 
during week 1. Patients received standard pre-medication 
and anti-infectious prophylaxis. Forty-eight patients were 
enrolled: 32 CLL, 9 CLL/prolymphocytic leukemia (PLL), 
1 PLL, 4 mantle-cell leukemia (MCL), 2 Richter transforma-
tion. Their median age was 62 years (range 44–79). Patients 
had received a median of 4 (range 1–9) prior therapies, 39 
(79%) had Rai stage  3 disease, and 26 (5%) were refractory 
to FAMP. The OR rate after a 4-week course of therapy was 
52%, including a CR rate of 8%. Among 32 patients with 
CLL , the OR was 63%. Treatment-related adverse events 
included expected infusion-related side effects (fever, skin 
reactions, fatigue, nausea, and vomiting), and infectious 
complications. About half of the patients experienced at 
least 1 infectious episode, including 7 patients (15%) with 
symptomatic CMV reactivation who responded to CMV-
directed therapy.
A different schedule was investigated in a phase-I study 
(Nabhan et al 2004). Rituximab was given at the standard 
dose of 375 mg/m2 on weeks 1, 3, 4, and 5 and alemtuzumab 
at 3 mg (ﬁ  rst cohort), 10 mg (second cohort), and eventu-
ally 30 mg (third cohort) 3 times weekly during weeks 2–5. 
Twelve patients were enrolled; all had failed prior purine-
analog-based therapy. One patient achieved PR whereas 
all remaining patients had stable disease. Treatment was 
well tolerated, with most toxicities related to the infusion of 
alemtuzumab. No opportunistic infections, particularly no 
CMV reactivation, were recorded.
Table 1 Responses to alemtuzumab as monotherapy in relapsed/refractory CLL
Reference  Schedule of treatment  No. pts   % OR/% CR   Route of
   evaluable    administration
Osterborg et al 1997  30 mg TIW × 12W  29  42/4  iv
Rai et al 2002  30 mg TIW × 16W  24  33/0  iv
Keating et al 2002  30 mg TIW × 12W  93  33/2  iv
McCune et al 2002  30 mg TIW × 12W  17  53/35  iv
Ferrajoli et al 2003  30 mg TIW × 12W  42  31/5  iv
Lozanski et al 2004  30 mg TIW × 12W  36  31/6  iv
Stilgenbauer et al 2004  30 mg TIW × 12W  50  37/4  sc
Moreton et al 2005  30 mg TIW × 16W  91  35/54  iv
Cortelezzi et al 2005  10 mg TIW × 18W  16  8/4  sc
Abbreviations: CR, complete response; iv, intravenous infusion; No, number; OR, overall response; pts, patients; TIW, 3 times a weeks; sc, subcutaneous injection; W, week.Biologics: Targets & Therapy 2008:2(1) 48
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In an effort to further optimize dose, schedule, and route 
of administration, obtain data about soluble CD52 serum 
levels and their association with prognosis, and gain easy 
access to subcutaneous alemtuzumab, the MD Anderson 
Cancer Center group investigated a continuous intravenous 
infusion (CIV) followed by SC injection of alemtuzumab 
plus rituximab (Faderl et al 2006). rituximab was given 
at 375 mg/m2 intravenously IV on day 1 followed by 500 
mg/m2 on days 8, 15, and 22, and alemtuzumab at 15 mg 
by continuous intravenous infusion daily for 6 days (days 
2–7) followed by 30 mg SC twice weekly on day 3 and 5 of 
weeks 2–4. Pre-medications and anti-infectious prophylaxis 
remained identical to those in previous regimens. Maximum 
duration of therapy was 3 courses. Forty-ﬁ  ve patients were 
enrolled of whom 32 patients were evaluable (30 CLL, 1 
CLL/SLL, 1 MZL). Six patients were too early and 7 were 
inevaluable. The median age was 59 years (range 39–78), the 
median number of prior therapies was 3 (1–8), and the median 
β2M 3.8 mg/dL (1.7–13.6). Seventeen patients (53%) had Rai 
stage  3 disease. Eighteen patients (56%) were refractory to 
FAMP and alkylators. All patients had prior rituximab; only 
4 (13%) had received alemtuzumab. Sixteen patients (50%) 
responded: 8 CR (25%), 1 PRn (3%), 7 PR (23%) following 
1 course. Response by site: peripheral blood 24/26 (92%), 
marrow 22/32 (69%), lymph nodes 13/26 (50%), and liver/
spleen 8/9 patients (89%). The combination was well toler-
ated with no unexpected toxicities. Most non-hematologic 
adverse events were infusion-related and   grade 2 by NCI 
toxicity criteria. Fevers and chills occurred in up to 56% of 
patients, fatigue in 34%, skin rashes in 19%, nausea in 16%, 
myalgias in 9%, and diarrhea in 6%. Although toxicites 
were more frequent with CIV alemtuzumab than during the 
SC injections, CIV alemtuzumab was well tolerated. CMV 
reactivation occurred in 7 patients (22%) and was the most 
common infectious complication.
Both combination, chemotherapeutic agents and mono-
clonal antibodies, have been tested by the CFAR regimen 
(CTX 250 mg/m2 days 3–5, FAMP 25 mg/m2 days 3–5, 
alemtuzumab 30 mg days 1/3/5, and rituximab 375–500 
mg/m2 day 2) in 74 patients with advanced CLL (Wierda et al 
2006). All patients received PCP and herpesviral prophylaxis, 
and the incidence of major infections (13% of patients) was 
not signiﬁ  cantly different from the historical experience 
with FAMP+CTX+rituximab (FCR). CMV reactivation 
occurred in 20% of patients, but was successfully treated in 
all but one; this patient died with multiple other infections. 
Of the 74 patients who received CFAR, 65% responded 
with complete response in 24%. Responses in patients with 
unfavorable cytogenetics (17p del, 11q del, complex and 6q 
del) included 14% CR and 50% PR; 44% of pts with 17p 
del responded.
Results obtained with alemtuzumab in combination are 
summarized in Table 2.
Alemtuzumab and p53 mutation
Of all prognostic factors examined in CLL, del(17p13.1), the 
chromosomal location of the tumor suppressor gene p53, has 
a superior predictive value for poor response to conventional 
therapy (Döhner et al 1995).
Stilgenbauer and colleagues were the ﬁ  rst to report a com-
plete response in a single patient with del(17p13.1) receiving 
alemtuzumab (Stilgenbauer and Dohner 2002).
More recently Lozanski et al (2004) reported the results 
observed in a cohort of 36 CLL patients (81% FAMP-
refractory) – 15 (42%) of whom had P53 mutations or 
deletions – treated with intravenous alemtuzumab. Muta-
tions of the p53 gene were assessed by amplifying each p53 
exon (5–9) individually from the genomic DNA. Clinical 
responses were noted in 6 of 15 patients (40%) with P53 
mutations and/or deletions, versus 4 of 21 patients (19%) 
without P53 abnormalities. The median response duration for 
this subset of patients was 8 months (range 3–17 months).
As previously reported, the interim analysis of the CLL2H 
trial conﬁ  rm the efﬁ  cacy of alemtuzumab in patients with 
p53 abnormalities (Stilgenbauer et al 2004). Moreover, one 
other retrospective study have conﬁ  rmed these responses 
in high-risk patients with p53 mutation (Osuji et al 2005). 
More importantly, one study examining alemtuzumab as 
initial therapy or in the relapsed setting given together 
with high-dose meyhylprednisolone conﬁ  rmed efﬁ  cacy of 
alemtuzumab in CLL patients with p53 mutation (Pettitt 
et al 2006).
These studies suggest that alemtuzumab therapy may be 
effective in a subgroup of patients with high-risk cytogenetic 
markers, which points to a potentially unique mechanism of 
action for alemtuzumab that is likely independent of a p53-
mediated pathway.
Safety and tolerability
Recently, management guidelines for use of alemtuzumab in 
CLL have been published (Keating et al 2004). In approxi-
mately 70%–80% of patients, initial infusions of alemtu-
zumab are associated with rigors, fever, rash, nausea and, 
less frequently, dyspnea and hypotension. Fever commonly 
begins 5–6 hours after the start of infusion. All of the above 
symptoms are of grade 1 and 2 severity in the majority of Biologics: Targets & Therapy 2008:2(1) 49
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patients, and are most common in the ﬁ  rst week of therapy, 
diminishing rapidly thereafter. Prophylactic use of antihista-
mines and acetaminophen, slowing of the infusion rate and, 
severe cases, limited use of steroids can largely abrogate 
these side effects.
Subcutaneous route of administration is a more conve-
nient alternative to alemtuzumab intravenous, is safe and 
appears to have similar efﬁ  cacy improving side-effect proﬁ  le 
compared with intravenous alemtuzumab.
Blood concentrations of IV or SC alemtuzumab have 
been measured in patients included in various clinical 
trials (Hale et al 2004). The highest measured blood 
concentrations of alemtuzumab were similar for IV 
administration ( 0.5–18.3 μg/mL, mean 5.4 μg/μL) and 
for SC administration (0.6–24.8 μg/mL, mean 5.4 μg/mL). 
The estimated half-life of alemtuzumab was 9 days for both 
modes of administration.
Hematologic side effects can occur in patients treated 
with alemtuzumab. Thrombocytopenia occurs most com-
monly during weeks 2–4 and neutropenia during weeks 
4–8. In general, these cytopenias are reversible and may 
be managed effectively by transfusion and growth factor 
support; discontinuation of therapy is not recommended. 
Severe lymphopenia , with reduction in both B and T-cells, 
is the most signiﬁ  cant hematologic effect of alemtuzumab. 
The ensuing immunosuppression, that often develops rapidly 
after the ﬁ  rst infusion, predisposed patients to infections 
with the most common being viral (varicella-zoster virus, 
herpes simplex virus, and CMV). Other infections include 
those caused by bacterial pathogens as well as opportunistic 
organisms. Routine use of antibacterial and antiviral pro-
phylaxis in more recent studies have been associated with 
a decreased incidence of infections (Ferrajoli et al 2003). 
Guidelines recently published recommend mandatory use 
of this strategy (Keating et al 2004).
The incidence of infections with alemtuzumab appears to 
be signiﬁ  cantly lower in previously untreated patients (Lundin 
et al 2002). In this study the recovery of immune cells was 
slow and the median cell count of all lymphoid subpopulations 
remained at less than 25% of the baseline values for greater 
than 9 months post treatment. Development of an EBV-positive 
lymphoprolipherative disorder after therapy with alemtuzumab 
has been reported and may be related to the profound immuno-
suppression associated with its use (Ghobrial et al 2003).
Recently reports of possible cardiac toxicity of alemtu-
zumab in patients with mycosis fungoides have been pub-
lished, but the lack of such reports in the earlier trials, where 
higher total doses of alemtuzumab were administered, would 
necessitate further conﬁ  rmation of any possible direct associa-
tion (Lenihan et al 2004).
Table 2 Responses to alemtuzumab in combination with chemotherapy or monoclonal antibodies in relapsed/refractory CLL
Reference Schedule of treatment No. pts evaluable % OR/% CR 
Kennedy et al 2002 FAMP 25 mg/m2 × 3 d Campath 30 
iv mg × 3 d/W every 28 d
6 83/17
Faderl et al 2003 Rituximab 375 mg/m2/W × 4W 
Campath 30 mg iv x 3 cd × 1W 30 
mg iv × 2 d/W × 2W x 2 courses
32 63/6
Nabhan et al 2004 Rituximab 375 mg/m2/W W 1-3-4-5 
Campath 3-0-30 mg iv × TIW W 2-5
12 8/0
Montillo et al 2007 FAMP 40 os mg/m2/d × 3 cd CTX 
250 os mg/m2/d × 3 cd Campath 10 
mg sc × 3 cd every 28 d × 6 courses
18 79/34
Elter et al 2005 Campath 30 iv sqm2 × 3 d FAMP 30 
mg/m2 × 3 d every 28 d × 6 courses
36 83/30
Faderl et al 2006 Campath 15 mg civ 24 h × 6 cd 30 
mg sc × 2 d/W × 3 W Rituximab 
375 mg/m2 d 1 500 mg/m2 d 8 d 15 
d 22 × 3 courses
32 50/25
Wierda et al 2006 C TX 250 mg/m2 days 3–5, FAMP 
25 mg/m2 days 3–5, Campath 30 
mg days 1, 3, 5, Rituximab 375–500 
mg/m2 day 2 × 6 courses 
74 65/24
Abbreviations: cd, consecutive days; civ, continuous intravenous infusion; CR, complete response; d, days; No, number; iv, intravenous infusion; OR, overall response; 
os, oral; pts, patients; sc, subcutaneous injection; TIW, 3 times a weeks; W, week.Biologics: Targets & Therapy 2008:2(1) 50
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Cytomegalovirus reactivation
The infectious toxicities of alemtuzumab have been well 
documented and are generally prevented with appropriate 
prophylactic medications. One topic of continued interest 
and concern is the issue of CMV reactivation. In the pivotal 
trial by Keating et al (2002b), in relapsed or refractory CLL 
patients, CMV reactivation occurred in 7.5% of patients. 
The typical presentation was fever and antigenemia. Organ 
involvement did not occur and there were no deaths. The Stan-
ford group had a similar experience (Nguyen et al 2002). Five 
out of 34 patients with relapsed and refractory CLL treated 
with alemtuzumab developed fever and CMV antigenemia. 
All patients had resolution of fever and antigenemia after 
therapy with ganciclovir. None of the 5 patients developed 
symptoms or ﬁ  ndings suggestive of a CMV-associated clinical 
syndrome. The Swedish group (Lundin et al 2002) reported 
CMV reactivation (veriﬁ  ed by polymerase chain reaction) 
following alemtuzumab therapy among 4 out of 41 (10%) 
previously untreated CLL patients. All 4 had fever without 
pneumonitis. These events occurred after 4, 5, 11, and 12 
weeks of alemtuzumab therapy, respectively. Three patients 
received intravenous ganciclovir treatment and responded 
promptly. One patient recovered spontaneously. In 2 of these 4 
cases, alemtuzumab treatment was restarted while the patient 
received oral ganciclovir prophylaxis without further CMV 
problems, The German CLL Study Group studied consolida-
tion with alemtuzumab in patients with CLL in ﬁ  rst remis  sion 
in a phase III randomized trial (Wendtner et al 2004). After a 
median of 4 weeks, alemtuzumab treatment was interrupted 
due to serious infections in 7 of 11 patients. Four patients 
showed CMV reactivation detected by CMV-speciﬁ  c PCR 
and required intravenous ganciclovir treatment because of 
rising viral load combined with fevers or because of CMV 
pneumonia. CMV pneumonia was diagnosed in 2 patients 
who had increased CMV titer by CMV-speciﬁ  c PCR, positive 
CMV antigen, radiological signs of pneumonia and clinical 
ﬁ  ndings of fever, dyspnea and coughing. Ganciclovir resolved 
the CMV symptoms and CMV-DNA declined to baseline lev-
els by week 8 in all treated patients. The clinical signiﬁ  cance 
of detection of CMV by plasma DNA PCR in patients with 
CLL treated with alemtuzumab remains uncertain, but this 
test provides an objective measure of CMV activity and may 
be diagnos  tic in patients with unexplained fever.
Updated guidelines providing recommendations for the 
management of CMV reactivation have been recently pub-
lished (O’Brien et al 2006). This new suggested approach to 
this topic is more aggressive incorporating surveillance/pre-
emptive therapy and up-front prophylaxis .
Nearly half of patients with treatment-naïve CLL receiv-
ing alemtuzumab therapy can present with asymptomatic 
CMV infection. Incidence of symptomatic infection among 
patients with previously untreated CLL is approximately 
10% even when a weekly CMV surveillance is ruled out. In 
contrast, the incidence of symptomatic reactivation among 
patients with previously treated CLL appears to decrease 
from approximately 30% to 9% with the regular CMV sur-
veillance and preemptive therapy. CMV surveillance might 
be considered labor-intensive and/or inaccessible for many 
treatment centers thus the authors suggested up-front pro-
phylaxis might be less labor – intensive because patients are 
treated with a CMV speciﬁ  c antiviral regimen regardless of 
their CMV antigenemia status (O’Brien et al 2006).
Based on our experience, in order to reduce an additional 
risk of myelosuppression and costs issue, up-front prophilaxis 
should be limited to patients with previous CMV reactivation 
or disease and/or in case of inaccessibility of surveillance 
tests, considering this last, together with pre-emptive therapy, 
as the preferable approach in the majority of patients.
Summary
The introduction of immunotherapeutic agents such as 
alemtuzumab is beginning to change the face of CLL treat-
ment. A considerable body of data is emerging through 
well designed clinical trials that can help guide clinicians 
to improve outcomes for patients with CLL, including 
those with advanced or refractory disease. Therapy with 
alemtuzumab offers a more effective option compared to 
combination chemotherapy for treatment of patients with 
CLL who have relapsed or who are refractory to nucleo-
side analogs. The response rate in patients with advanced 
disease inversely correlates with the presence and size of 
the lymph nodes. However, patients not fulﬁ  lling the cri-
teria for PR with regard to lymphoadenopathy may have 
tumor reduction in the bone marrow, with improvements 
in disease-related symptoms and cytopenia. A number of 
therapeutic strategies are being evaluated to improve this 
outcome even further. Combination therapy with other 
immunologic or chemotherapeutic agents may accomplish 
this goal. alemtuzumab is particularly effective in patients 
with p53 mutations. Signiﬁ  cant efforts are being made 
to identify patients who will not respond optimally to 
conventional therapy as patients with p53 mutations. The 
earlier use of alemtuzumab in this high-risk patients may 
produce improved responses while avoiding unnecessary 
toxicities accompanying suboptimal therapies. Although 
there are signiﬁ  cant potential toxicities associated with Biologics: Targets & Therapy 2008:2(1) 51
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alemtuzumab, such the infusional reactions and the risk 
of CMV reactivation, most are manageable. Infusional 
reactions can be reduced by prophylactic administration of 
antihistamines and paracetamol or by adding corticosteroids 
IV during the ﬁ  rst week of treatment. Alternatively, SC 
administration is associated with fewer ﬂ  u-like symptoms 
than IV administration. All patients receiving alemtuzumab 
therapy must be rigorously checked for emerging infections. 
In particular CMV quantitative polymerase chain reaction 
or antigenemia should be performed routinely or at least 
without any delay in all febrile patients, as early administra-
tion of valgancyclovir may be very effective.
In conclusion, alemtuzumab is an important drug in the 
treatment of CLL having an unique properties not shared by 
chemotherapeutic agents or other monoclonal antibodies. It 
can be incorporated into various treatment modalities (eg, 
consolidation, combination with chemotherapy, maintenance 
therapy) to improve clinical outcomes in a wide range of 
patients with CLL. Additional randomized phase III trials 
are urgently warranted.
References
Byrd JC, Stilgenbauer S, Flinn IW. 2004. Chronic lymphocytic leukemia. 
In: Hematology American Society of Hematology Education Pro-
gram Book. Washington, DC: American Society of Hematology. 
p.163–83.
Catovsky D, Richards S, Matutes E, et al. 2007. Assessment of ﬂ  udarabine 
plus cyclophosphamide for patients with chronic lymphocytic leu-
kaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet, 
370:230–9.
Cheson BD, Bennet JM, Grever M, et al. 1996. National Cancer 
Institute – sponsored Working Group Guidelines for chronic lympho-
cytic leukemia: revised guidelines for diagnosis and treatment. Blood, 
87:4990–7.
Cortelezzi A, Pasquini MC, Sarina B, et al. 2005. A pilot study of 
low-dose subcutaneous alemtuzumab therapy for patients with 
chemotherapy-refractory chronic lymphocytic leukemia. Haemato-
logica, 90:410–12.
Delannoy A, Hanique G, Ferrant A. 1993. 2-Chlorodeoxyadenosine for 
patients with B-cell chronic lymphocytic leukemia resistant to ﬂ  uda-
rabine. N Engl J Med, 328:812.
Dohner H, Fischer K, Bentz M, et al. 1995. p53 gene deletion predicts for 
poor survival and non-response to therapy with purine analogs in chronic 
B-cell leukemias. Blood, 85:1580–9.
Eichhorst BF, Busch R, Hopﬁ  nger G, et al. 2006. Fludarabine plus cyclo-
phosphamide versus ﬂ  udarabine alone in ﬁ  rst line therapy of younger 
patients with chronic lymphocytic leukemia. Blood, 107:885–91.
Elter T, Borchmann P, Schulz H, et al. 2005. Fludarabine in combination 
with alemtuzumab is effective and feasible in patients with relapsed 
or refractory B-cell chronic lymphocytic leukemia: results of a phase 
II trial. J Clin Oncol, 23:7024–31
Faderl S, Thomas DA, O’Brien S. et al. 2003. Experience with alemtuzumab 
plus rituximab in patients with relapsed and refractory lymphoid malig-
nancies. Blood, 101:3413–15.
Faderl S, Ferrajoli A, Wierda WG, et al. 2006. The combination of 
Alemtuzumab [Continuous Intravenous Infusion (civ) followed by 
subcutaneous injection (sc)] plus Rituximab has activity in patients 
(pts) with relapsed chronic lymphocytic leukemia (CLL) [abstract]. 
Blood, 108:2827.
Ferrajoli A, O’Brien SM, Cortes JE. et al. 2003. Phase II study of alemtuzumab 
in chronic lymphoproliferative disorders. Cancer, 98:773–8.
Flinn IW, Neuberg DS, Grever MR, et al. 2007. Phase III Trial of Fludarabine 
Plus Cyclophosphamide Compared With Fludarabine for Patients With 
Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup 
Trial E2997. J Clin Oncol, 25:793–8.
Ghobrial IM, Otteman LA, White WL. 2003. An EBV-positive lymphop-
roliferative disorder after therapy with alemtuzumab. N Engl J Med, 
349:2570–2.
Gilleece MH and Dexter TM. 1993. Effect of Campath-1H antibody on 
human hematopoietic progenitors in vitro. Blood, 82:807–812.
Greenwood J, Clark M, Waldmann H. 1993. Structural motifs involved in 
human IgG antibody effector functions. Eur J Immunol, 23:1098–104.
Grever MR, Leiby JM, Kraut EH, et al. 1985. Low-dose deoxycoformycin 
in lymphoid malignancy. J Clin Oncol, 3:1196–201.
Hale G, Rebello P, Brettman LR, et al. 2004. Blood concentrations of 
alemtuzumab and antiglobulin responses in patients with chronic 
lymphocytic leukemia following intravenous or subcutaneous routes 
of administration. Blood, 104:948–55.
Heit W, Bunjes D, Wiesneth M, et al. 1986. Ex vivo T-cell depletion with the 
monoclonal antibody Campath-1 plus human complement effectively 
prevents acute graft-versus-host disease in allogenic bone marrow 
transplantation. Br J Haematol, 64:479–86.
Johnson S, Smith AG, Lofﬂ  er H, et al. 1996. Multicentre prospective ran-
domized trial of ﬂ  udarabine versus cyclophosphamide, doxorubicin, 
and prednisone (CAP) for treatment of advanced-stage chronic lym-
phocytic leukaemia. The French Cooperative Group on CLL. Lancet, 
347:1432–8.
Juliusson G, Elmhorn-Rosenborg A, Liliemark J. 1992. Response to 2-
chlorodeoxyadenosine in patients with B-cell chronic lymphocytic 
leukemia resistant to ﬂ  udarabine. N Engl J Med, 327:1056–61.
Keating MJ, Kantarjian H, Talpaz M, et al. 1989. Fludarabine: a new agent 
with major activity against chronic lymphocytic leukemia. Blood, 
74:19–25.
Keating MJ, O’Brien S, Kantarjian H, et al. 1993. Long-term follow-up of 
patients with chronic lymphocytic leukemia treated with ﬂ  udarabine 
as a single agent. Blood, 81:2878–84.
Keating MJ, O’Brien S, Kontoyannis D, et al. 2002a. Results of ﬁ  rst salvage 
therapy for patients refractory to a ﬂ  udarabine regimen in chronic 
lymphocytic leukemia. Leuk Lymphoma, 43:1755–62.
Keating MJ, Flinn I, Jain V, et al. 2002b. Therapeutic role of alemtuzumab 
(Campath-1H) in patients who have failed ﬂ  udarabine: results of a large 
international study. Blood, 99:3554–61.
Keating MJ, Coutre S, Rai K, et al. 2004. Management guidelines for 
use of Alemtuzumab in B-cell chronic lymphocytic leukemia. Clin 
Lymphoma, 4:220–7.
Kennedy B, Rawstron A, Carter C, et al. 2002. Campath-1H and ﬂ  udarabine 
in combination are highly active in refractory chronic lymphocytic 
leukemia. Blood, 99:2245–7.
Kipps TJ . 2001. Chronic lymphocytic leukemia and related diseases. In: 
Williams Hematology. Beutler E, Lichtman MA, Coller BS, Kipps TJ, 
Seligsohn U (eds). Mc.Graw-Hill. New York, USA, 1163–1194.
Knospe WH, Loeb V Jr, Huguley CM Jr. 1974. Proceedings: Bi-weekly 
chlorambucil treatment of chronic lymphocytic leukemia. Cancer, 
33:555–62.
Lenihan DJ, Alencar AJ, Yang D, et al. 2004. Cardiac toxicity of alemtu-
zumab in patients with mycosis fungoides/Sezary syndrome. Blood, 
104:655–8.
Leporrier M, Chevret S, Cazin B, et al. 2001. Randomized comparison of 
ﬂ  udarabine, CAP, and CHOP in 938 previously untreated stage B and 
C chronic lymphocytic leukemia patients. Blood, 98:2319–25.
Lozanski G, Heerema NA, Flinn IW, et al. 2004. Alemtuzumab is an 
effective therapy for chronic lymphocytic leukemia with p53 mutations 
and deletions. Blood, 103: 3278–81.
Lundin J, Kimby E, Bjorkholm M, et al. 2002. Phase II trial of subcutaneous 
alemtuzumab (Campath-1H) as ﬁ  rst-line treatment for patients with B-
cell chronic lymphocytic leukemia (B-CLL). Blood, 100:768–773.Biologics: Targets & Therapy 2008:2(1) 52
Montillo et al
McCune SL, Gockerman JP, Moore JO, et al. 2002. Alemtuzumab in 
relapsed or refractory chronic lymphocytic leukemia and prolympho-
cytic leukemia. Leuk Lymphoma, 43:1007–1011.
Montserrat E. 2002. Current and developing chemotherapy for CLL. Med 
Oncol, 19:S11–S19.
Montillo M, Tedeschi A, Miqueleiz S, et al. 2007. Combined ﬂ  udarabine, 
cyclophosphamide, and alemtuzumab (FCC), an active regimen for 
treated patients with chronic lymphocytic leukemia (CLL) [abstract]. 
Blood, 110:3133.
Moreton P, Kennedy B, Lucas G, et al. 2005. Eradication of minimal 
residual disease in B-cell chronic lymphocytic leukemia after alem-
tuzumab therapy is associated with prolonged survival. J Clin Oncol, 
23:2971–9.
Nabhan C, Rosen ST. 2002. Conceptual aspects of combining rituximab and 
Campath-1H in the treatment of chronic lymphocytic leukemia. Semin 
Oncol, 29 (Suppl 2):75–80.
Nabhan C, Patton D, Gordon LI, et al. 2004. A pilot trial of rituximab and 
alemtuzumab combination therapy in patients with relapsed and/or 
refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma, 
45:2269–73.
Nguyen DD, Cao TM, Dugan K, et al. 2002. Cytomegalovirus viremia 
during CAMPATH-1H therapy for relapsed and refractory chronic 
lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma, 
3:105–110.
O’Brien S, Kantarijan H, Estey E, et al. 1994. Lack of effect of 2-chlorode-
oxyadenosine therapy in patients with chronic lymphocytic leukaemia 
refractory to ﬂ  udarabine therapy. N Engl J Med, 330:319–22.
O’Brien S, Keating MJ, Mocarski ES. 2006. Updated guidelines on the 
management of Cytomegalovirus reactivation in patients with chronic 
lymphocytic leukemia treated with Alemtuzumab. Clin Lymphoma 
Myeloma, 7:125–30
Oken MM, Kaplan ME. 1979. Combination chemotherapy with cyclophos-
phamide, vincristine, and prednisone in the treatment of refractory 
chronic lymphocytic leukemia. Cancer Treat Rep, 63:441–7.
Osterborg A, Dyer MJ, Bunjes D, et al. 1997. Phase II multicenter study 
of human CD52 antibody in previously treated chronic lymphocytic 
leukemia. European Study Group of CAMPATH-1H Treatment in 
Chronic Lymphocytic Leukemia. J Clin Oncol, 15:1567–74.
Osuji NC, Del Giudice I, Matutes E, et al. 2005. The efﬁ  cacy of alemtuzumab 
for refractory chronic lymphocytic leukemia in relation to cytogenetic 
abnormalities of p53. Haematologica, 90:1435–6.
Pettitt AR, Matutes E, Oscier D. 2006. Alemtuzumab in combination with 
high-dose methylprednisolone is a logical, feasible and highly active 
therapeutic regimen in chronic lymphocytic leukaemia patients with 
p53 defects. Leukemia, 20:1441–5.
Rai KR, Peterson BL, Appelbaum FR, et al. 2000. Fludarabine compared 
with chlorambucil as primary therapy for chronic lymphocytic leukemia. 
N Engl J Med, 343:1750–7.
Rai KR, Freter CE, Mercier RJ, et al. 2002. Alemtuzumab in previously 
treated chronic lymphocytic leukemia patients who also had received 
ﬂ  udarabine. J Clin Oncol, 20:3891–7.
Rossmann ED, Lundin J, Lenkei R, et al. 2001. Variability in B-cell antigen 
expression: implications for the treatment of B-cell lymphomas and 
leukemias with monoclonal antibodies. Hematol J, 2:300–6.
Rowan W, Tite J, Topley P, et al. 1998. Cross-linking of the Campath-1 
antigen (CD52) mediates growth inhibition in human B- and T-lym-
phoma cell lines, and subsequent emergence of CD52-deﬁ  cient cells. 
Immunology, 95:427–36.
Sayala HA, Moreton P, Jones RA, et al. 2006. Final report of the UKCLL02 
Trial: A phase II study of subcutaneous alemtuzumab plus ﬂ  udarabine 
in patients with ﬂ  udarabine refractory CLL (on behalf of the NCRI 
CLL Trials Sub-Group) [abstract]. Blood, 108:34.
Saven A, Piro LD. 1993. 2-Chlorodeoxyadenosine: a new nucleoside agent 
effective in the treatment of lymphoid malignancies. Leuk Lymphoma, 
10(Suppl):43–9.
Stilgenbauer S, Dohner H. 2002. Campath-1H-induced complete remis-
sion of chronic lymphocytic leukemia despite p53 gene mutation and 
resistance to chemotherapy. N Engl J Med, 347: 452–3.
Stilgenbauer S, Winkler D, Krober A, et al. 2004. Subcutaneous Campath-1H 
(alemtuzumab) in ﬂ  udarabine  refractory refractory CLL; interim analy-
sis of the CLL2H Study of the German CLL Study Group (GCLLSG) 
[abstract]. Blood, 104:478.
Wendtner CM, Ritgen M, Schweighofer CD, et al. 2004. Consolidation 
with alemtuzumab in patients with chronic lymphocytic leukemia in 
ﬁ  rst remission- experience on safety and efﬁ  cacy within a randomized 
multicenter phase III trial of the German CLL Study Group (GCLLSG). 
Leukemia, 18:1093–101.
Wierda W, O’Brien S, Faderl S, et al. 2006. Combined cyclophosphamide, 
ﬂ  udarabine, alemtuzumab, and rituximab (CFAR), an active regimen 
for heavily treated patients with CLL [abstract]. Blood, 108:31.